{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:05:22Z","timestamp":1790208322355,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2010003 and 2022YFC3601002"],"award-info":[{"award-number":["2022YFC2010003 and 2022YFC3601002"]}]},{"name":"\"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang Province","award":["2023C03083"],"award-info":[{"award-number":["2023C03083"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13824-3","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:06:23Z","timestamp":1783008383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing COVID-19 vaccination for older adults: superior efficacy of heterologous regimens in reducing infection and mortality rates among patients aged 80 years and older during the Omicron BA.5\/BF.7 outbreak"],"prefix":"10.1186","volume":"26","author":[{"given":"Songlin","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"17","key":"13824_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.46234\/ccdcw2023.070","volume":"5","author":"D Fu","year":"2023","unstructured":"Fu D, He G, Li H, Tan H, Ji X, Lin Z, et al. Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023. China CDC Wkly. 2023;5(17):369\u201373.","journal-title":"China CDC Wkly"},{"issue":"7","key":"13824_CR2","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jamda.2020.05.045","volume":"21","author":"C Bonanad","year":"2020","unstructured":"Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-Gonzalez V, Facila L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020;21(7):915\u20138.","journal-title":"J Am Med Dir Assoc"},{"key":"13824_CR3","doi-asserted-by":"crossref","unstructured":"Funk T, Innocenti F, Gomes Dias J, Nerlander L, Melillo T, Gauci C, et al. Age-specific associations between underlying health conditions and hospitalisation, death and in-hospital death among confirmed COVID-19 cases: a multi-country study based on surveillance data, June to December 2020. Euro Surveill. 2022;27(35).","DOI":"10.2807\/1560-7917.ES.2022.27.35.2100883"},{"issue":"5","key":"13824_CR4","doi-asserted-by":"publisher","first-page":"e0250602","DOI":"10.1371\/journal.pone.0250602","volume":"16","author":"X Li","year":"2021","unstructured":"Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS ONE. 2021;16(5):e0250602.","journal-title":"PLoS ONE"},{"key":"13824_CR5","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.lanepe.2021.100097","volume":"5","author":"KE Bennett","year":"2021","unstructured":"Bennett KE, Mullooly M, O\u2019Loughlin M, Fitzgerald M, O\u2019Donnell J, O\u2019Connor L, et al. Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: A national surveillance study. Lancet Reg Health Eur. 2021;5:100097.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"13824_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.7326\/M20-6979","volume":"174","author":"GJ Escobar","year":"2021","unstructured":"Escobar GJ, Adams AS, Liu VX, Soltesz L, Chen YI, Parodi SM, et al. Racial Disparities in COVID-19 Testing and Outcomes: Retrospective Cohort Study in an Integrated Health System. Ann Intern Med. 2021;174(6):786\u201393.","journal-title":"Ann Intern Med"},{"issue":"7","key":"13824_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.7326\/M20-3936","volume":"174","author":"U Bilal","year":"2021","unstructured":"Bilal U, Tabb LP, Barber S, Diez Roux AV. Spatial Inequities in COVID-19 Testing, Positivity, Confirmed Cases, and Mortality in 3 U.S. Cities: An Ecological Study. Ann Intern Med. 2021;174(7):936\u201344.","journal-title":"Ann Intern Med"},{"issue":"3","key":"13824_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41591-023-02241-7","volume":"29","author":"G Wang","year":"2023","unstructured":"Wang G, Yao Y, Wang Y, Gong J, Meng Q, Wang H, et al. Determinants of COVID-19 vaccination status and hesitancy among older adults in China. Nat Med. 2023;29(3):623\u201331.","journal-title":"Nat Med"},{"issue":"4","key":"13824_CR9","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/S2666-7568(22)00035-6","volume":"3","author":"L Arregoces-Castillo","year":"2022","unstructured":"Arregoces-Castillo L, Fernandez-Nino J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincon-Medrano L, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 2022;3(4):e242\u201352.","journal-title":"Lancet Healthy Longev"},{"issue":"2","key":"13824_CR10","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2666-7568(20)30011-8","volume":"1","author":"LS Cox","year":"2020","unstructured":"Cox LS, Bellantuono I, Lord JM, Sapey E, Mannick JB, Partridge L, et al. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev. 2020;1(2):e55\u20137.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"13824_CR11","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/s41467-023-40489-2","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xu N, Xu Y, Qin P, Dai R, Xu B, et al. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults. Nat Commun. 2023;14(1):4757.","journal-title":"Nat Commun"},{"issue":"6","key":"13824_CR12","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","volume":"10","author":"A Jara","year":"2022","unstructured":"Jara A, Undurraga EA, Zubizarreta JR, Gonzalez C, Pizarro A, Acevedo J, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798\u2013806.","journal-title":"Lancet Glob Health"},{"key":"13824_CR13","doi-asserted-by":"crossref","unstructured":"Xu X, Hong Y, Chen E, Wang Y, Ma B, Li J, et al. Antibodies induced by homologous or heterologous inactivated (CoronaVac\/BBIBP-CorV) and recombinant protein subunit vaccines (ZF2001) dramatically enhanced inhibitory abilities against B.1.351, B.1.617.2, and B.1.1.529 variants. Vaccines (Basel). 2022;10(12).","DOI":"10.3390\/vaccines10122110"},{"issue":"8","key":"13824_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"JX Li","year":"2022","unstructured":"Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739\u201348.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"13824_CR15","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","volume":"13","author":"F Zuo","year":"2022","unstructured":"Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13(1):2670.","journal-title":"Nat Commun"},{"issue":"10324","key":"13824_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521\u20139.","journal-title":"Lancet"},{"key":"13824_CR17","doi-asserted-by":"publisher","unstructured":"Li T. PUMCH COVID-19 Working Group. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect. 2020;9(1):582\u2013585. https:\/\/doi.org\/10.1080\/22221751.2020.1735265","DOI":"10.1080\/22221751.2020.1735265"},{"key":"13824_CR18","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.","journal-title":"BMJ"},{"issue":"8","key":"13824_CR19","first-page":"e208","volume":"21","author":"H Catherine","year":"2021","unstructured":"Catherine H, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(8):e208.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"13824_CR20","doi-asserted-by":"publisher","first-page":"e044640","DOI":"10.1136\/bmjopen-2020-044640","volume":"11","author":"BG Pijls","year":"2021","unstructured":"Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640.","journal-title":"BMJ Open"},{"issue":"5","key":"13824_CR21","doi-asserted-by":"publisher","first-page":"e2210780","DOI":"10.1001\/jamanetworkopen.2022.10780","volume":"5","author":"K Furukawa","year":"2022","unstructured":"Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, et al. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open. 2022;5(5):e2210780.","journal-title":"JAMA Netw Open"},{"key":"13824_CR22","doi-asserted-by":"publisher","first-page":"e074325","DOI":"10.1136\/bmj-2022-074325","volume":"382","author":"NW Andersson","year":"2023","unstructured":"Andersson NW, Thiesson EM, Baum U, Pihlstrom N, Starrfelt J, Faksova K, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023;382:e074325.","journal-title":"BMJ"},{"issue":"3","key":"13824_CR23","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S2666-5247(22)00290-7","volume":"4","author":"D Saure","year":"2023","unstructured":"Saure D, O\u2019Ryan M, Torres JP, Zuniga M, Soto-Rifo R, Valiente-Echeverria F, et al. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study. Lancet Microbe. 2023;4(3):e149\u201358.","journal-title":"Lancet Microbe"},{"key":"13824_CR24","doi-asserted-by":"publisher","first-page":"103761","DOI":"10.1016\/j.ebiom.2021.103761","volume":"75","author":"R Gross","year":"2022","unstructured":"Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2022;75:103761.","journal-title":"EBioMedicine"},{"issue":"9","key":"13824_CR25","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","volume":"27","author":"T Schmidt","year":"2021","unstructured":"Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination. Nat Med. 2021;27(9):1530\u20135.","journal-title":"Nat Med"},{"issue":"10","key":"13824_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmi.2022.04.019","volume":"28","author":"S Bae","year":"2022","unstructured":"Bae S, Ko JH, Choi JY, Park WJ, Lim SY, Ahn JY, et al. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity. Clin Microbiol Infect. 2022;28(10):1390. e1- e7.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"13824_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","volume":"74","author":"R Link-Gelles","year":"2025","unstructured":"Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, et al. Interim Estimates of 2024\u20132025 COVID-19 Vaccine Effectiveness Among Adults Aged >\/=18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(6):73\u201382.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"13824_CR28","doi-asserted-by":"publisher","first-page":"e2557415","DOI":"10.1001\/jamanetworkopen.2025.57415","volume":"9","author":"KC Ma","year":"2026","unstructured":"Ma KC, Webber A, Lauring AS, Bendall E, Papalambros LK, Safdar B, et al. Estimated Effectiveness of 2024\u20132025 COVID-19 Vaccination Against Severe COVID-19. JAMA Netw Open. 2026;9(2):e2557415.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13824-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:37:47Z","timestamp":1790206667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13824-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13824"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13824-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants followed the ethical standards of the study hospital and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study has received ethical approval from the Taizhou Hospital Ethics Committee in Zhejiang Province (Approval No.: K20230116). Because this retrospective study was based on existing clinical records and laboratory data, and all patient-identifiable information was anonymized, the Ethics Committee of Taizhou Hospital of Zhejiang Province waived the requirement for informed consent in accordance with applicable ethical guidelines.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to publish. And no identifying images or other personal or clinical details of participants are presented that compromise anonymity in this manuscript, the statement of consent to publish from the patient is not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1712"}}